Literature DB >> 30455234

Role of Therapeutic Drug Monitoring in Treatment Optimization in Tuberculosis and Diabetes Mellitus Comorbidity.

B G J Dekkers1, O W Akkerman2,3, J W C Alffenaar4.   

Abstract

Entities:  

Keywords:  azithromycin; diabetes mellitus; ethambutol; moxifloxacin; pharmacokinetics; pyrazinamide; rifampin; therapeutic drug monitoring; tuberculosis

Mesh：

Substances：

Year:  2019        PMID： 30455234      PMCID： PMC6355609          DOI： 10.1128/AAC.02074-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  11 in total

1.  Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes.

Authors:  Hanneke M J Nijland; Rovina Ruslami; Janneke E Stalenhoef; Erni J Nelwan; Bachti Alisjahbana; Ron H H Nelwan; Andre J A M van der Ven; Halim Danusantoso; Rob E Aarnoutse; Reinout van Crevel
Journal:  Clin Infect Dis       Date:  2006-08-22       Impact factor: 9.079

Review 2.  Tuberculosis and diabetes mellitus: convergence of two epidemics.

Authors:  Kelly E Dooley; Richard E Chaisson
Journal:  Lancet Infect Dis       Date:  2009-12       Impact factor: 25.071

Review 3.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

4.  Effect of Diabetes Mellitus on the Pharmacokinetics and Pharmacodynamics of Tuberculosis Treatment.

Authors:  Omamah Alfarisi; Vidya Mave; Sanjay Gaikwad; Tushar Sahasrabudhe; Geetha Ramachandran; Hemanth Kumar; Nikhil Gupte; Vandana Kulkarni; Sona Deshmukh; Sachin Atre; Swapnil Raskar; Rahul Lokhande; Madhusudan Barthwal; Arjun Kakrani; Sandy Chon; Amita Gupta; Jonathan E Golub; Kelly E Dooley
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

5.  Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability.

Authors:  Shashikant Srivastava; Jotam G Pasipanodya; Claudia Meek; Richard Leff; Tawanda Gumbo
Journal:  J Infect Dis       Date:  2011-10-21       Impact factor: 5.226

Review 6.  Implications of the global increase of diabetes for tuberculosis control and patient care.

Authors:  Rovina Ruslami; Rob E Aarnoutse; Bachti Alisjahbana; Andre J A M van der Ven; Reinout van Crevel
Journal:  Trop Med Int Health       Date:  2010-11       Impact factor: 2.622

7.  Effects of type 2 diabetes mellitus on the population pharmacokinetics of rifampin in tuberculosis patients.

Authors:  Min Jung Chang; Jung-Woo Chae; Hwi-Yeol Yun; Jangik I Lee; Hye Duck Choi; Jihye Kim; Jong Sun Park; Young-Jae Cho; Ho Il Yoon; Choon-Taek Lee; Wan Gyoon Shin; Jae-Ho Lee
Journal:  Tuberculosis (Edinb)       Date:  2014-11-15       Impact factor: 3.131

8.  Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India.

Authors:  A K Hemanth Kumar; T Kannan; V Chandrasekaran; V Sudha; A Vijayakumar; K Ramesh; J Lavanya; S Swaminathan; G Ramachandran
Journal:  Int J Tuberc Lung Dis       Date:  2016-09       Impact factor: 2.373

9.  Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus.

Authors:  Aylin Babalik; Ismail Hakki Ulus; Nadi Bakirci; Tulin Kuyucu; Huseyin Arpag; Lale Dagyildizi; Esen Capaner
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

10.  Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes.

Authors:  Rovina Ruslami; Hanneke M J Nijland; I Gusti N Adhiarta; Sri H K S Kariadi; Bachti Alisjahbana; Rob E Aarnoutse; Reinout van Crevel
Journal:  Antimicrob Agents Chemother       Date:  2009-12-28       Impact factor: 5.191
View more
  4 in total

Review 1.  Tuberculosis and comorbidities: treatment challenges in patients with comorbid diabetes mellitus and depression.

Authors:  Guillermo Cáceres; Rodrigo Calderon; Cesar Ugarte-Gil
Journal:  Ther Adv Infect Dis       Date:  2022-05-20

2.  Increased Moxifloxacin Dosing Among Patients With Multidrug-Resistant Tuberculosis With Low-Level Resistance to Moxifloxacin Did Not Improve Treatment Outcomes in a Tertiary Care Center in Mumbai, India.

Authors:  Jeffrey A Tornheim; Zarir F Udwadia; Prerna R Arora; Ishita Gajjar; Samridhi Sharma; Megha Karane; Namrata Sawant; Nisha Kharat; Alexander J Blum; Shri Vijay Bala Yogendra Shivakumar; Akshay N Gupte; Nikhil Gupte; Jai B Mullerpattan; Lancelot M Pinto; Tester F Ashavaid; Amita Gupta; Camilla Rodrigues
Journal:  Open Forum Infect Dis       Date:  2021-12-23       Impact factor: 3.835

Review 3.  Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?

Authors:  Eva Choong; Alain Sauty; Angela Koutsokera; Sylvain Blanchon; Pascal André; Laurent Decosterd
Journal:  Pharmaceutics       Date:  2022-08-11       Impact factor: 6.525

4.  Diagnostic Accuracy of Therapeutic Drug Monitoring During Tuberculosis Treatment.

Authors:  Ginger Anderson; Christopher Vinnard
Journal:  J Clin Pharmacol       Date:  2022-06-13       Impact factor: 2.860
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.